Novartis hints at higher offer for Alcon; Malaria group announces first partnership;

 @FierceBiotech: GSK orders Sirtris execs to stop selling resveratrol. Article  | Follow @FierceBiotech

> Novartis AG CEO Joe Jimenez left open the possibility the Swiss drugmaker may raise its $9.8 billion offer to buy out eye-care company Alcon's minority shareholders. Report

> The Medicines for Malaria Venture (MMV) today became the first product development partnership to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline, Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology in contributing to the Pool, which is administered by BIO Ventures for Global Health. MMV release

> Chongqing Lummy Pharmaceutical and Jiangsu Lianhuan Pharmaceutical led gains among Chinese drugmakers in Shanghai and Shenzhen trading after a news website reported the companies make medicines that can combat a drug-resistant bacteria. Article

> Morphotek, a subsidiary of Eisai, announced today that the John Wayne Cancer Institute in Santa Monica, California has opened enrollment in a Phase I clinical study with MORAb-028 in patients with advanced melanoma. Morphotek release

> KemPharm announced today that it has received a Notice of Issuance from the USPTO for its patent application titled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same," U.S. Patent No. 7,772,222.  KemPharm release

And Finally... When the North Carolina Biotechnology Center awarded Thrombotargets a loan to further its research on ways to stop bleeding, the company was riding high on promising news from regulators and touting its lead candidate as a potential blockbuster. Today, there is no sign of progress on the company's bleeding treatment. In fact, there's very few signs of the company at all: Phones at Thrombotargets' Durham offices go unanswered, and the company has cut communication with its scientific advisers. Story

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.